|
1
|
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
|
Blood
|
1997
|
2.13
|
|
2
|
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
|
Blood
|
1999
|
1.89
|
|
3
|
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
|
Blood
|
1995
|
1.45
|
|
4
|
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
|
J Clin Oncol
|
1990
|
1.39
|
|
5
|
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
|
Blood
|
1988
|
1.36
|
|
6
|
Homoharringtonine: history, current research, and future direction.
|
Cancer
|
2001
|
1.25
|
|
7
|
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.
|
Blood
|
2000
|
1.07
|
|
8
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
Blood
|
1999
|
0.96
|
|
9
|
Innovative strategies for the treatment of CLL.
|
Leuk Lymphoma
|
1996
|
0.93
|
|
10
|
Splenectomy for immune thrombocytopenic purpura.
|
Arch Surg
|
1981
|
0.93
|
|
11
|
High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
|
Blood
|
1994
|
0.92
|
|
12
|
Autotransplants in multiple myeloma: what have we learned?
|
Blood
|
1996
|
0.90
|
|
13
|
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
|
J Clin Oncol
|
2000
|
0.87
|
|
14
|
Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
|
Blood
|
1990
|
0.86
|
|
15
|
Clinical trials referral resource. Clinical trials with pyrazoloacridine.
|
Oncology (Williston Park)
|
1997
|
0.80
|
|
16
|
New chemotherapeutic agents in non-small-cell lung cancer.
|
Semin Oncol
|
1993
|
0.79
|
|
17
|
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
|
Ann Oncol
|
1999
|
0.78
|
|
18
|
Clinical trials referral resource.
|
Oncology (Williston Park)
|
1997
|
0.75
|
|
19
|
Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.
|
Oncology (Williston Park)
|
2001
|
0.75
|
|
20
|
High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.
|
Blood
|
1990
|
0.75
|
|
21
|
International harmonization of trial parameters in malignant lymphoma.
|
Eur J Haematol Suppl
|
2005
|
0.75
|